ArticleFoods (Basel, Switzerland)2026
Ellagic Acid Prevents Obesity in High-Fat Diet-Fed Rats by Ameliorating Oxidative Stress via Modulation of the PPARG/STAT3/p-AKT1 Axis.
Article in Foods (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
This study investigated the protective effects and underlying mechanisms of ellagic acid (EA) against high-fat diet (HFD)-induced obesity. Using network pharmacology, STAT3 and AKT1 were identified as pivotal regulatory targets. In vivo experiments demonstrated that EA intervention significantly reduced body weight inducement, improved lipid profiles, and attenuated intestinal oxidative stress and inflammation in HFD-fed rats. Furthermore, EA restored intestinal architecture and mitochondrial morphology. Mechanistically, EA markedly downregulated the expression of PPARG, STAT3 and p-AKT1 in both intestinal tissues and TNF-α-stimulated HaCaT cells. Collectively, these findings suggest that EA prevents HFD-induced obesity by alleviating intestinal oxidative stress and mitochondrial dysfunction through the modulation of the PPARG/STAT3/p-AKT1 signaling axis. This study provides novel evidence for EA as a potential natural bioactive compound for the management of metabolic disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.